Live Breaking News & Updates on Susan Galbraith

Stay updated with breaking news from Susan galbraith. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

AstraZeneca and Daiichi Sankyo announce positive results from phase 3 lung cancer study

AstraZeneca and Daiichi Sankyo announce positive results from phase 3 lung cancer study
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

Susan-galbraith , Ken-takeshita , Daiichi-sankyo , European-society-for-medical-oncology-congress , Medical-oncology ,

AstraZeneca experimental lung cancer drug shows promising results

AstraZeneca’s experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday. ....

Japan , Ken-takeshita , Daiichi-sankyo , Susan-galbraith , Astrazeneca ,

AstraZeneca-Daiichi's Dato-DXd didn't prove OS benefit in phase 3

Daiichi Sankyo and ADC partner AstraZeneca have already filed Dato-DXd with the FDA, but the latest readout casts a shadow over the application. ....

David-fredrickson , Rd-ken-takeshita , Daiichi-sankyo , Susan-galbraith , Astrazeneca , European-society-for-medical-oncology , Fierce-biotech , European-society , Medical-oncology , Gilead-science-trodelvy ,

Dato-DXd Elicits Clinically Meaningful OS Improvement in Previously Treated, Advanced NSCLC

Dato-DXd Elicits Clinically Meaningful OS Improvement in Previously Treated, Advanced NSCLC
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

Daiichi-sankyo , Ken-takeshita , Susan-galbraith , Astrazeneca ,

Why Is AstraZeneca Stock Trading Lower On Tuesday? - AstraZeneca (NASDAQ:AZN)

AstraZeneca's TROPION-Lung01 phase 3 trial for datopotamab deruxtecan in NSCLC showed OS improvement in nonsquamous patients. While the overall trial did not reach statistical significance. ....

Susan-galbraith , Daiichi-sankyo , Astrazeneca-plc , European-society-for-medical-oncology , Astrazeneca , Astrazeneca-targets-ambitious , European-society , Medical-oncology , Executive-vice-president ,